We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

New Control Helps Monitor C. difficile Assays with Higher Confidence

By LabMedica International staff writers
Posted on 31 Aug 2014
Print article
Image: The ACCURUN 501 C. difficile Control set for use with human stool samples improves diagnostic assay performance monitoring and reliability of results (Photo courtesy of Gregg Shupe, SeraCare Life Sciences and PRNewsFoto).
Image: The ACCURUN 501 C. difficile Control set for use with human stool samples improves diagnostic assay performance monitoring and reliability of results (Photo courtesy of Gregg Shupe, SeraCare Life Sciences and PRNewsFoto).
A ready-to-use Clostridium difficile control set for use with human stool samples improves diagnostic assay performance-monitoring and reliability of results.

SeraCare Life Sciences, Inc. (Milford, MA, USA), a provider of products that help optimize performance across the in vitro diagnostics (IVD) lifecycle and bridge the gap between current diagnostic solutions and emerging technologies, has now added to its portfolio the “ACCURUN 501 C. difficile Control” – SeraCare’s first molecular control product targeting hospital acquired infections. The control set is formulated for use with IVD tests that detect C. difficile DNA in human stool samples and is ready-to-use in such tests with any transport system. Prepared from cultured Clostridium of 4 different strains or species delivered in a set of 4 vials, the bacteria are inactivated and in a human synthetic stool matrix.

"Hospital acquired infection assays present unique sample challenges which require dependable, whole cell controls. Our new ACCURUN 501 product is a full process control that is intended to not only estimate laboratory testing performance but also immediately detect analytical errors and monitor the entire testing process. As a result, our customers have greater confidence in fulfilling their QC requirements," said Christopher Long, product manager at SeraCare.

Related Links:

SeraCare Life Sciences
ACCURUN 501 C. difficile Control set


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.